Results 141 to 150 of about 12,862 (201)

Necrolytic acral erythema in an incarcerated population: A case series. [PDF]

JAAD Case Rep
Ali I, Cavanagh M, Kelly BC.
europepmc   +1 more source

Investigating the time-dependent withdrawal effects of sofosbuvir and/or ribavirin on male mice: a histological and histophotometrical approach. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Shahat EH, Shabaka HAE, Ali EHA, Ahmed S, Zakaria I.   +4 more
europepmc   +1 more source

Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting. [PDF]

Eur J Clin Microbiol Infect Dis
Pokorska-Śpiewak M, Dobrzeniecka A, Talarek E, Aniszewska M, Marczyńska M.   +4 more
europepmc   +1 more source

Safety and efficacy of different therapeutic regimens in Egyptian adults with moderate COVID-19 infection (EVEREST): a real-world retrospective study. [PDF]

Sci Rep
Abdel-Salam Elgohary M, Hamza N, Ali A, Zaher Abdel-Rahman R, Thabet Elnagar M, Emam Mohamed M, Seadawy MG, Zenhom Abdelfatah M, Taha NA, Rauof M, El-Bouseary MM.   +10 more
europepmc   +1 more source

The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis. [PDF]

Medicina (Kaunas)
Mah SM, Sid'Ahmed S, Lemrabott M, Welli D, Awa J, Sidi Aly A, Rostaing L.   +6 more
europepmc   +1 more source

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report. [PDF]

Ann Med Surg (Lond)
Sajjad W, Rehman UU, Inam A, Alam I, Ghafoor S, Razzaq HD, Khwajakhail T, Gillani SHMUD, Razzaq H, Qamar I, Ali R, Ullah Z.   +11 more
europepmc   +1 more source

Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study. [PDF]

Medicine (Baltimore)
Park HJ, Wang H, Jeong J, Seo KI, Shin JW, Park NH.   +5 more
europepmc   +1 more source

Economic evaluation of alternative hepatitis C treatment options: a post hoc analysis of the VIETNARMS trial. [PDF]

EClinicalMedicine
Turner HC, Ahmed S, Nguyen HA, Hung LM, Van Nuil J, Thuan DT, SEARCH investigators, Dung NT, Thwaites GE, Walker AS, Chau NVV, Cooke GS, Hallett TB.   +12 more
europepmc   +1 more source

Trends in Utilization and Costs Following a Hepatitis C Elimination Initiative. [PDF]

JAMA Netw Open
Tabah A, Basu A, Cox-North P, Zerzan-Thul J, Evaskus L, Sullivan D, Colson J, Huriaux E, Stockton J, Heidari O, Wiggins L, Chang S, Kohler P.   +12 more
europepmc   +1 more source